Increased effectiveness of allylamine drug compounds for...

Details Increased effectiveness of allylamine drug compounds for... Increased effectiveness of allylamine drug compounds for...

2008-02-05

2011-11-08

Arnold, Ernst (Department: 1613)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Biocides; animal or insect repellents or attractants

C424S061000, C514S078000, C514S655000, C514S772000, C514S944000, C514S946000, C514S947000, C514S975000

Reexamination Certificate

active

08052984

ABSTRACT:
The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment; the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive charge. The positive charge and enhancers used in the formula allow for increased penetration of the active ingredient through skin and skin appendages. The positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The bead structure minimizes the molecular diffusion of the positively charged active ingredient and a catalytic species through the bead structure, thus stabilizes the positively charged active ingredient inside the bead by impeding the interaction of the positively charged active ingredient and the catalytic species, and thereby extending the shelf life of the positively charged active ingredient.

REFERENCES:
patent: 5696164 (1997-12-01), Sun et al.
patent: 5814305 (1998-09-01), Laugier et al.
patent: 5885260 (1999-03-01), Mehl, Sr. et al.
patent: 6183451 (2001-02-01), Mehl, Sr. et al.
patent: 6916479 (2005-07-01), Embrechts et al.
patent: 7135194 (2006-11-01), Birnbaum
patent: 7740875 (2010-06-01), Dechow
patent: 7820720 (2010-10-01), Cevc et al.
patent: 2002/0086039 (2002-07-01), Lee et al.
patent: 2003/0068365 (2003-04-01), Suvanprakorn et al.
patent: 2004/0224012 (2004-11-01), Suvanprakorn et al.
patent: 2005/0244522 (2005-11-01), Carrara et al.
patent: 2006/0024243 (2006-02-01), Arkin et al.
patent: 2006/0052438 (2006-03-01), Ho et al.
patent: 2006/0058256 (2006-03-01), Breitenbach et al.
patent: 2006/0110342 (2006-05-01), Dechow
patent: 2006/0163752 (2006-07-01), Wang et al.
patent: 101035509 (2010-11-01), None
patent: WO-2006/042059 (2006-04-01), None
Budavari et al., editior, “The Merck Index” 12th edition, 1996.
International Search Report and Written Opinion mailed Jun. 2, 2008 for PCCT/US08/01492, filed Feb. 5, 2008.
Prescribing Information “Lamisil” Novartis Pharmaeuticals Canada Inc., Date of Preparation: Apr. 28, 1993; Date of Revision: Mar. 2, 2010.
Supplementary European Search Report mailed on Mar. 2, 2010, for European Patent Application No. EP 08725165 filed on Feb. 5, 2008.
Youenang et al., “Positively and negatively charged submicron emulsions for enhanced topical delivery of antifungal drugs,” Journal of Controlled Release, vol. 58, pp. 177-187 (Mar. 29, 1999).
Barquero, “The treatment of Distal subungual onychomycosis (DSO) in toe nails byTrichophyton rubrumwith 1% terbinafine gel vs. placebo,” Act. Tera. Dermatol. , vol. 30, pp. 352-353 (2007) English translation.
Gupta et al., “A brief history on onychomycosis treatment,” J. Am Acad Dermatol, 67th Annual Meeting Mar. 6-10, 2009, San Francisco , California, Abstract 2413, pp. AB114 (Mar. 2009).
Gupta et al., “Onychomycosis therapy: Past, Present, Future,” Journal of Drugs in Dermatology, vol. 9, pp. 1109-1113 (2010).
Gupta et al., “Update in antifungal therapy of dermatophytosis,” Mycopathologia, vol. 166, pp. 353-367 (2008).
Lu Bin, “Pharmaceuticsm” China Medical Science Press, (2003-01), pp. 21-23.
Savin et al.,“Treatment of chronic moccassin type tinea pedis with terbinafine; a double-blind, placebo controlled,” J. Am. Acad Dermatol, vol. 23, pp. 804-807 (1990).
Shemer et al., “Ciclopirox nail lacquer for the treatment of onychomycosis: An open non-comparative study,” Journal of Dermatology, vol. 37, pp. 137-139 (2010).
Zaias et al,. “Treatment of tineas pedis with Griseofluvin and topical antifungal cream,” Cutis, vol. 22, pp. 196-199 , Aug. 1978.
Smith et al., “Comparison of once and twice daily naftifine cream regimens with twice daily clotrimazole in the treatment of tinea pedis,” JAAD info, vol. 22, No. 6,Part I, pp. 1116-1117 (1990).
Zaias and Cooperative study group, “Naftifine gel in the treatment of Tinea Pedis: two double-blind,” Multicenter Studies, 1989.
Zaias et al., “A Method for the determination of drug effectiveness in onychomycosis. Trials with Ketonazole and griseofulvin ultramicrosize,” journal American Academy Derm. vol. 9, pp. 912-919 (Dec. 1983).
Zaias et al., “The successful treatment of fingerTrichophyton rubrumOnychomycosis with oral terbinafine,” Clinical and experimental Dermatology, vol. 14, pp. 120-123 (1989).
Zaias et al., “superficial Mycoses. Treatment with a new broad spectrum antifungal: 1% clotrimazole solution,” Arch. Derm, vol. 113 , pp. 307-308 (1977).
Zaias, “Onychomycosis,” Arch. Derm., vol. 105, pp. 263-274 (Feb. 1972).
Zaias, “Onychomycosis,” Dermatol Clin. vol. 3, pp. 445-460 (1985).
Zaias et al., “The management of childhood onychomycosis,” Pediatric Dermatology, vol. 21, pp. 80-81 (2004).
Zaias et al., “The successful treatment ofTrichophyton rubrumNail bed (distal subungual) Onychomycosis with internittent pulse-dosed terbinafine,” Archives of dermatology, vol. 140, pp. 691-695, Jun. 2004.
Zaias et al., “Onychomycosis treated until the nail is replaced by normal growth or there is failure,” Arch Dermatol, vol. 136, p. 940, (2000).
Zaias et al.,“Management of Onychomycosis with oral Terbinafine,” J. Am. Acad Dermatol, vol. 23, pp. 810-812 (1990).
Zaias N., “Clinical Manifestations of Onychomycosis,” Clin Exp. Dermatol, vol. 17S, pp. 6-7 (1992).
Berman et al., Efficacy of a 1-week, twice daily Regimen of Terbinafine 1% cream in the treatment of interdigital Tinea Pedis, J. Am. Acad Dermatol, vol. 26, pp. 956-960 (1992).
Savin et al., “Efficacy of Terbinafine 1% cream in the treatment of mocassin -type Tinea Pedis: Results of Placebo-Controlle Mutlicenter Trials,” Journal of American Academy of Dermatology, vol. 30, pp. 663-667 (1994).
Bergstresser et al., “Topical Terbinafine and clotrimazole in interdigital tinea Pedis: A mullti-center comparison of cure and relapse-rates with 1-week and 4-week treatment regimens,” J. Am Acad Dermatol, vol. 28, pp. 648-651 (1993).
Elewsky et al., “Long term outcome of patients with interdigital tinea Pedis treated with Terbinafine or Clotrimazole,” J. Am. Acad. Dermatol, vol. 32, pp. 290-292 (1995).
Elewsky et al., “Comparison of an Antifungal Agent used alone with an antifungal used with a topical steroid in inflammatory Tineas Pedia,” Cutis, vol. 58, pp. 305-307 (1996).
Zaias et al., “Diagnosing and treating onychomycosis,” J. Family Practice, vol. 42, pp. 513-518 (1996).
Zaias et al., “Chronic dermatolhytosis syndrome due toTrichophyton rubrum,” International Journal Dermatology, vol. 35, pp. 614-617 (1996).
Zaias et al., “Autosomal dominant pattern of distal subungual onychomycosis caused byTrichophyton rubrum,” J.Am. Acad Derm, vol. 34, pp. 302-304 (1996).
Jones et al., “Double-blind, randomized comparison of Itraconazole capsules and placebo in onychomycosis of toenail,” Int. J. Dermatology, vol. 35, pp. 589-590 (1996).
Zaias N, et al., Efficacy of a 1-week, once-daily regimen of terbinafine 1% cream in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol; vol. 29: pp. 646-648 (1993).
Elewsky et al., “Double-blind randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis,” Cutis, vol. 59, pp. 217-220 (1997).
Zaias et al., “Candida: A Review of the clinical experience in lamisil,” Dermatology, vol. 194, pp. 10-13 (1997).
Odom et al., “A multicenter, placenbo-controlled, double-blind study of Intermittent therapy with intraconazole for the treatment of Onychomycosis of the fingernail,” J. Am. Acad. Dermatol. , vol. 36, pp. 231-235 (1997).
Konst

Affiliated with

Also associated with

Rating

Increased effectiveness of allylamine drug compounds for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Increased effectiveness of allylamine drug compounds for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increased effectiveness of allylamine drug compounds for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4305177